Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

LBA28 The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

Post-surgery ctDNA was detected in 35/135 (26%). Relapse occurred in 12/35 (34%) ctDNA-positive vs 9/100 (9%) ctDNA-negative patients (HR 4.37, P=0.0003); the 9 negative relapses were the prespecified false-negative count. After 3 months of CAPOX, 11/35 positive patients converted to negative, but 8/11 later relapsed or re-positivized. Of 23 who received FOLFIRI after CAPOX, 11 converted and were relapse-free at analysis.

ESMO Congress 2023